Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Michal Bar-Natan, John Mascarenhas, Aaron T. Gerds, Ruben Mesa, Vikas Gupta, Marina Kremyanskaya, Mikaela Dougherty, Frank Fabris, Kathryn Johnson, Ashley Yu, Heidi E. Kosiorek, Carolyn Mead-Harvey, Amylou C. Dueck, Ronald Hoffman, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 3988–3990.

https://doi.org/10.1182/blood-2022-164678

Published: 2022

Journal Articles

Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm

Laura F. Mendez, Jiarui Li, Julio Avelar-Barragan, Jenny Nguyen, Hellen Nguyen, Heidi E. Kosiorek, Ruben Mesa, Robyn Marie Scherber, Katrine Whiteson, Andrew Odegaard, Angela G Fleischman

Blood (2022) 140 (Supplement 1): 3972–3973.

https://doi.org/10.1182/blood-2022-168865

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Blood (2021) 138 (Supplement 1): 142.

https://doi.org/10.1182/blood-2021-148995

Published: 2021

Journal Articles

Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR- mutated Essential Thrombocythemia (ET) Patients

Shira Rosenberg, Andrea Kubas-Meyer, Neelang Parghi, Nathaniel D. Omans, Neville Dusaj, Paulina Chamely, Eleni Mimitou, Amylou C. Dueck, Heidi E. Kosiorek, Rona Singer Weinberg, Peter Smibert, Ronan Chaligne, Dan A. Landau, Ronald Hoffman, Anna S Nam

Blood (2021) 138 (Supplement 1): 57.

https://doi.org/10.1182/blood-2021-150745

Published: 2021

Journal Articles

An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy

Adrienne Kaufman, Yael Kusne, Molly Klanderman, Heidi E. Kosiorek, Thomas Oliver, Miguel Gonzalez-Velez, Robert D. McBane, Waldemar E. Wysokinski, Damon E. Houghton, Leslie Padrnos

Blood (2021) 138 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2021-154453

Published: 2021

Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-140830

Published: 2020

Journal Articles

Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care

Blake T. Langlais, MS, Carolyn Mead-Harvey, MS, Heidi E. Kosiorek, MS, Gina L. Mazza, PhD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-143172

Published: 2020

Journal Articles

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Jeanne M. Palmer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Camoriano, MD, Craig Zimmerman, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-138934

Published: 2020

Journal Articles

Photodynamic Therapy in Refractory Mycosis Fungoides: A Prospective, Open-Label Study

Caitlin M Brumfiel, M.S., Kevin J Severson, B.A., Meera H Patel, B.S., Helen J L Cumsky, MD, Brenda F Ginos, B.A., Heidi E. Kosiorek, MS, Monica C Janeczek, MD, Jake Besch-Stokes, B.S., William Rule, MD, David DiCaudo, MD, Allison C. Rosenthal, D.O., Mark R Pittelkow, MD, Aaron R Mangold, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-141119

Published: 2020

Journal Articles

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Gina L. Mazza, PhD, Carolyn Mead-Harvey, MS, John Mascarenhas, MD, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, Heidi E. Kosiorek, MS, Josef T. Prchal, MD, Richard T. Silver, MD, Tiziano Barbui, MD, Amylou C. Dueck, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-142817

Published: 2020

Journal Articles

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138953

Published: 2020

Journal Articles

Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Miguel Gonzalez Velez, MD, Carolyn Mead-Harvey, MS, Heidi E. Kosiorek, MS, Yael Kusne, MD PhD, Leyla Bojanini, MD, Candido E. Rivera, MD, Donald Northfelt, MD, Chung-II Wi, MD, Leslie Padrnos, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-142897

Published: 2020

Journal Articles

Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019

Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD, Blake T. Langlais, MS

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-137809

Published: 2020

Journal Articles

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

Blake T. Langlais, MS, Heidi E. Kosiorek, MS, Gina L. Mazza, PhD, Carolyn Mead-Harvey, MS, Richard Butterfield, III, Jeanne M. Palmer, MD, Ruben Mesa, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142838

Published: 2020

Journal Articles

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Miguel Gonzalez-Velez, MD, Mariano Arribas, Heidi E. Kosiorek, MS, Richard Butterfield, III, Carlo Guerrero, MD, Luke Mountjoy, DO, Jeremy Larsen, Craig B. Reeder, MD, P. Leif Bergsagel, MD, A. Keith Stewart, MB, ChB, Rafael Fonseca, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142845

Published: 2020

Journal Articles

Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study

Ruben Mesa, MD, Heidi E. Kosiorek, MS, Alessandra Carobbio, BSc, Tiziano Barbui, MD, Amylou C. Dueck, PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-134583

Published: 2020

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Andrew Dunbar, MD, Heidi E. Kosiorek, MS, Aishwarya Krishnan, Erin McGovern, BA, Young Park, BS, Minal A Patel, MPH, Rona Singer Weinberg, PhD, Abdulraheem Yacoub, MD, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 1661.

https://doi.org/10.1182/blood-2019-129571

Published: 2019

Journal Articles

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Bridget Marcellino, MD PhD, Joseph Tripodi, Michal Bar-Natan, MD, Harry Fruchtman, Noushin Farnoud, PhD, Min Lu, PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Vesna Najfeld, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4207.

https://doi.org/10.1182/blood-2019-129565

Published: 2019

NARROW

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR- mutated Essential Thrombocythemia (ET) Patients

An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Photodynamic Therapy in Refractory Mycosis Fungoides: A Prospective, Open-Label Study

Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma

Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only